Daily Ards Research Analysis

BACKGROUND: Drug-induced acute respiratory distress syndrome (ARDS) represents an often overlooked yet potentially severe adverse reaction in clinical practice. Existing evidence predominantly stems from isolated case reports, and systematic investigations based on large-scale real-world data remain limited. This study aimed to comprehensively evaluate the risk signals of drug-related ARDS and identify potential high-risk drug classes using the US FDA Adverse Event Reporting System (FAERS). METHODS: We retrieved data from FAERS and extracted ARDS-related reports based on the MedDRA Preferred Terms (PT), followed by deduplication and data cleaning. Four disproportionality analysis methods were used to detect drug signals. LASSO regression and multivariable logistic regression were applied to identify potential independent risk factors. The time interval from drug exposure to ARDS onset was also assessed. RESULTS: A total of 15,986 drug-related ARDS reports were included, with the highest proportion occurring in middle-aged and older adults, and slightly more cases in males than in females. The five most frequently reported drugs were mycophenolic acid, methotrexate, rituximab, tacrolimus, and amiodarone. Signal detection indicated strong associations for prednisone, mycophenolic acid, amiodarone, and cytarabine. Multivariable analyses further identified 22 drugs significantly associated with ARDS risk. The median time to ARDS onset was 30 days, and approximately 75% of cases occurred within 150 days after treatment initiation. CONCLUSION: Using real-world data, this study identified multiple drug classes with significantly elevated ARDS risk, including immunosuppressants, antineoplastic agents, glucocorticoids, cardiovascular drugs, and nonsteroidal anti-inflammatory drugs (NSAIDs). These findings provide important evidence for clinical monitoring of high-risk medications.

ARDS is a life-threatening lung disease marked by severe AECS and ECs damage, causing rapid lung function loss and high mortality. MSCs are promising therapies due to their immunoregulatory and regenerative properties. While early studies highlighted MSCs' anti-inflammatory effects in ARDS, recent findings emphasize their essential role in repairing the AECs and ECs. In this review, we detail the molecular mechanisms and synergistic effects of MSCs in epithelial and endothelial repair. We also examine how MSC-mediated immune regulation intersects with tissue repair, explore new combination approaches using drugs, gene editing, and bioengineering, and outline clinical limitations and ongoing challenges. Patient heterogeneity, disease stage, treatment timing, and safety issues limit the conduct of clinical trials and their translation. We summarize the roles, limitations, and challenges of MSCs in ARDS to guide future research and inform the development of new treatments.

PURPOSE: Obesity is increasingly encountered among patients requiring extracorporeal membrane oxygenation (ECMO) for severe respiratory or cardiac failure. It alters respiratory and cardiovascular physiology and drug pharmacokinetics and introduces technical and logistical challenges that may complicate patient selection, ECMO initiation, cannulation, anticoagulation, and monitoring. This review summarizes current evidence regarding the epidemiology, physiological implications, outcomes, and management of obesity in patients supported with veno-venous (VV) or veno-arterial (VA) ECMO. RESULTS: Available evidence, largely retrospective and based on body mass index classifications, suggests that obesity should not be considered a contraindication to VV-ECMO, with outcomes comparable to or potentially better than those of patients without obesity. However, obesity-related respiratory mechanics may exaggerate the apparent severity of lung injury, emphasizing the need for optimized conventional ARDS management, including appropriate ventilatory strategies and prone positioning, before ECMO initiation. In contrast, outcomes during VA-ECMO are more heterogeneous, particularly in extracorporeal cardiopulmonary resuscitation (ECPR), and may be influenced by patient selection, comorbidities, and timing of support. Obesity also creates important technical challenges requiring individualized cannulation, anticoagulation, and perfusion strategies. CONCLUSION: Obesity alone should not preclude access to ECMO, particularly VV-ECMO. Successful management requires anticipation of obesity-related challenges, appropriate infrastructure, and structured multidisciplinary protocols. Further prospective studies are needed to clarify obesity-specific risks, optimize management strategies, and evaluate long-term outcomes.